ArticlesBio-Plex Multiplex ImmunoassaysResearch Highlights

CAR T-Cell Therapy and the Cytokine Storm: The Balancing Act at the Center of Next-Generation Cancer Therapies

Recent advances in chimeric antigen receptor (CAR) T-cell therapy have opened exciting new avenues for the treatment of a variety of malignancies. Cytokine release syndrome (CRS), a powerful immune response to activated CAR T cells, is the primary side effect of CAR T-cell therapy, but existing CRS treatments can make CAR T-cell treatment less effective. In two recent studies, researchers used multiplexed cytokine immunoassays to better understand how CAR T-cell therapy triggers CRS and to identify strategies for early intervention in CRS development.
READ MORE →